| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
|
N Engl J Med
|
2006
|
22.86
|
|
2
|
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
|
Blood
|
2013
|
8.00
|
|
3
|
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
|
N Engl J Med
|
2003
|
6.68
|
|
4
|
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).
|
Blood
|
2010
|
3.97
|
|
5
|
The role of FLT3 in haematopoietic malignancies.
|
Nat Rev Cancer
|
2003
|
3.97
|
|
6
|
Regulation of myeloid leukaemia by the cell-fate determinant Musashi.
|
Nature
|
2010
|
3.20
|
|
7
|
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.
|
Blood
|
2010
|
3.15
|
|
8
|
MicroRNA discovery and profiling in human embryonic stem cells by deep sequencing of small RNA libraries.
|
Stem Cells
|
2008
|
3.14
|
|
9
|
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.
|
Blood
|
2009
|
2.87
|
|
10
|
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.
|
Blood
|
2008
|
2.80
|
|
11
|
Clinical implications of FLT3 mutations in pediatric AML.
|
Blood
|
2006
|
2.72
|
|
12
|
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.
|
J Clin Oncol
|
2009
|
2.64
|
|
13
|
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
|
Blood
|
2009
|
2.36
|
|
14
|
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.
|
J Natl Compr Canc Netw
|
2009
|
2.25
|
|
15
|
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.
|
Blood
|
2013
|
2.23
|
|
16
|
Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.
|
Blood
|
2005
|
2.22
|
|
17
|
Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
|
Blood
|
2004
|
2.18
|
|
18
|
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.
|
Blood
|
2002
|
2.12
|
|
19
|
IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development.
|
Cancer Cell
|
2011
|
2.05
|
|
20
|
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
|
Blood
|
2007
|
2.05
|
|
21
|
Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.
|
J Clin Oncol
|
2005
|
2.04
|
|
22
|
Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients.
|
Sci Transl Med
|
2013
|
1.78
|
|
23
|
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.
|
Blood
|
2003
|
1.65
|
|
24
|
Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML.
|
Blood
|
2006
|
1.65
|
|
25
|
Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.
|
Blood
|
2012
|
1.57
|
|
26
|
BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment.
|
Clin Cancer Res
|
2011
|
1.56
|
|
27
|
Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia.
|
Blood
|
2007
|
1.52
|
|
28
|
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.
|
Biol Blood Marrow Transplant
|
2006
|
1.47
|
|
29
|
Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.
|
Blood
|
2006
|
1.46
|
|
30
|
Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia.
|
Blood
|
2007
|
1.46
|
|
31
|
Identification of genes with abnormal expression changes in acute myeloid leukemia.
|
Genes Chromosomes Cancer
|
2008
|
1.46
|
|
32
|
Signatures of environmental exposures using peripheral leukocyte gene expression: tobacco smoke.
|
Cancer Epidemiol Biomarkers Prev
|
2004
|
1.44
|
|
33
|
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
|
Blood
|
2010
|
1.44
|
|
34
|
Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia.
|
Blood
|
2003
|
1.43
|
|
35
|
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
|
Blood
|
2009
|
1.42
|
|
36
|
Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes.
|
Blood
|
2004
|
1.41
|
|
37
|
The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.
|
Blood
|
2012
|
1.35
|
|
38
|
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.
|
J Clin Oncol
|
2012
|
1.30
|
|
39
|
The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data.
|
Blood
|
2009
|
1.23
|
|
40
|
FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.
|
Blood
|
2006
|
1.17
|
|
41
|
Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia.
|
Blood
|
2004
|
1.17
|
|
42
|
Structural and numerical variation of FLT3/ITD in pediatric AML.
|
Blood
|
2008
|
1.16
|
|
43
|
The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.
|
Blood
|
2009
|
1.11
|
|
44
|
Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia.
|
Biol Blood Marrow Transplant
|
2005
|
1.10
|
|
45
|
The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.
|
Blood
|
2006
|
1.08
|
|
46
|
Chronic Myelogenous Leukemia, Version 1.2014.
|
J Natl Compr Canc Netw
|
2013
|
1.07
|
|
47
|
Single-stranded linear amplification protocol results in reproducible and reliable microarray data from nanogram amounts of starting RNA.
|
Genomics
|
2004
|
1.07
|
|
48
|
Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2006
|
1.06
|
|
49
|
Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia.
|
Br J Haematol
|
2004
|
1.05
|
|
50
|
Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS?
|
Br J Haematol
|
2007
|
1.05
|
|
51
|
Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.
|
Br J Haematol
|
2010
|
1.04
|
|
52
|
Chronic myelogenous leukemia, version 1.2015.
|
J Natl Compr Canc Netw
|
2014
|
1.02
|
|
53
|
Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop.
|
Leuk Lymphoma
|
2012
|
1.01
|
|
54
|
DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells.
|
Blood
|
2008
|
1.01
|
|
55
|
Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation.
|
Biol Blood Marrow Transplant
|
2003
|
1.00
|
|
56
|
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia.
|
Biol Blood Marrow Transplant
|
2005
|
0.98
|
|
57
|
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.
|
Br J Haematol
|
2013
|
0.98
|
|
58
|
Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia.
|
Biol Blood Marrow Transplant
|
2003
|
0.96
|
|
59
|
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia.
|
Blood
|
2011
|
0.94
|
|
60
|
Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG.
|
Blood
|
2011
|
0.91
|
|
61
|
Progenitor cell involvement is predictive of response to induction chemotherapy in paediatric acute myeloid leukaemia.
|
Br J Haematol
|
2003
|
0.89
|
|
62
|
Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases.
|
Int J Hematol
|
2002
|
0.89
|
|
63
|
NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.
|
J Natl Compr Canc Netw
|
2011
|
0.88
|
|
64
|
Development of an integrated assay for detection of BCR-ABL RNA.
|
Clin Chem
|
2007
|
0.88
|
|
65
|
Chronic myelogenous leukemia.
|
J Natl Compr Canc Netw
|
2012
|
0.84
|
|
66
|
Pretransplant MRD: the light is yellow, not red.
|
Blood
|
2012
|
0.83
|
|
67
|
An evolutionary explanation for the presence of cancer nonstem cells in neoplasms.
|
Evol Appl
|
2012
|
0.82
|
|
68
|
Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation.
|
Leuk Lymphoma
|
2002
|
0.82
|
|
69
|
Fanconi anemia type C-deficient hematopoietic cells are resistant to TRAIL (TNF-related apoptosis-inducing ligand)-induced cleavage of pro-caspase-8.
|
Exp Hematol
|
2004
|
0.81
|
|
70
|
Methylenetetrahydrofolate reductase genotype affects risk of relapse after hematopoietic cell transplantation for chronic myelogenous leukemia.
|
Clin Cancer Res
|
2004
|
0.81
|
|
71
|
Molecular classification of acute myeloid leukemia: are we there yet?
|
J Clin Oncol
|
2008
|
0.80
|
|
72
|
Self-digitization microfluidic chip for absolute quantification of mRNA in single cells.
|
Anal Chem
|
2014
|
0.80
|
|
73
|
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia.
|
BMC Cancer
|
2013
|
0.80
|
|
74
|
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study.
|
Int J Hematol
|
2014
|
0.80
|
|
75
|
NCCN task force report: molecular markers in leukemias and lymphomas.
|
J Natl Compr Canc Netw
|
2009
|
0.79
|
|
76
|
Chronic myelogenous leukemia.
|
J Natl Compr Canc Netw
|
2007
|
0.78
|
|
77
|
Molecular targets in acute myelogenous leukemia.
|
Blood Rev
|
2003
|
0.78
|
|
78
|
The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemia.
|
PLoS One
|
2013
|
0.78
|
|
79
|
Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: which parameter at which time-point does matter?
|
Am J Hematol
|
2010
|
0.78
|
|
80
|
Monitoring patients with chronic myeloid leukemia receiving Abl tyrosine kinase inhibitor therapy.
|
Clin Lymphoma Myeloma
|
2007
|
0.78
|
|
81
|
Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia.
|
Curr Oncol Rep
|
2003
|
0.77
|
|
82
|
Allogeneic transplant for chronic myeloid leukemia in 2010.
|
Ther Adv Hematol
|
2010
|
0.75
|
|
83
|
Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.
|
Am J Hematol
|
2011
|
0.75
|
|
84
|
Comparison of Two Methods for Detecting Alternative Splice Variants Using GeneChip(®) Exon Arrays.
|
Int J Biomed Sci
|
2011
|
0.75
|
|
85
|
Chronic myelogenous leukemia.
|
J Natl Compr Canc Netw
|
2005
|
0.75
|
|
86
|
Sequential therapy in chronic myelogenous leukemia: where do emerging therapies fit within current treatment regimens?
|
Clin Adv Hematol Oncol
|
2013
|
0.75
|
|
87
|
Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study.
|
Arch Pathol Lab Med
|
2013
|
0.75
|
|
88
|
Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction.
|
Curr Hematol Malig Rep
|
2006
|
0.75
|
|
89
|
Use of gene expression microarrays for the study of acute leukemia.
|
Expert Rev Mol Diagn
|
2006
|
0.75
|